User profiles for Alexandre de Nonneville
 | Alexandre de NonnevilleAix-Marseille University, Institut Paoli Calmettes, CRCM, Marseille, France Verified email at ipc.unicancer.fr Cited by 612 |
[HTML][HTML] Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers
A De Nonneville, G Houvenaeghel, M Cohen… - European Journal of …, 2022 - Elsevier
… The authors declare the following financial interests/personal relationships which may be
considered as potential competing interests: Alexandre de Nonneville declares the following …
considered as potential competing interests: Alexandre de Nonneville declares the following …
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
In some types of cancer, telomere length is maintained by the alternative lengthening of
telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation …
telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation …
[HTML][HTML] Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX
A De Nonneville, RR Reddel - Nature Communications, 2021 - nature.com
The PCAWG Consortium has recently released an integrative re-analysis of a large set of
tumor whole genome sequence (WGS) data from 2658 cancer patients across 38 different …
tumor whole genome sequence (WGS) data from 2658 cancer patients across 38 different …
[HTML][HTML] Expression of X-linked inhibitor of apoptosis protein (XIAP) in breast cancer is associated with shorter survival and resistance to chemotherapy
GR Devi, P Finetti, MA Morse, S Lee, A de Nonneville… - Cancers, 2021 - mdpi.com
Simple Summary The X-linked inhibitor of apoptosis protein (XIAP) is considered the most
potent inhibitor of cell death, and it is well established that XIAP promotes resistance to …
potent inhibitor of cell death, and it is well established that XIAP promotes resistance to …
WEE1 dependency and pejorative prognostic value in triple‐negative breast cancer
A de Nonneville, P Finetti, D Birnbaum… - Advanced …, 2021 - Wiley Online Library
In their recent paper,[1] Lamballe et al. identify the combination treatment with BCL-XL and
WEE1 inhibitors as a promising therapeutic approach in triple-negative breast cancer (TNBC)…
WEE1 inhibitors as a promising therapeutic approach in triple-negative breast cancer (TNBC)…
[HTML][HTML] Enhanced recovery after surgery program in Gynaecologic Oncological surgery in a minimally invasive techniques expert center
E Lambaudie, A de Nonneville, C Brun, C Laplane… - BMC surgery, 2017 - Springer
Background Enhanced Recovery After Surgery Programs (ERP) includes multimodal
approaches of perioperative patient’s clinical pathways designed to achieve early recovery after …
approaches of perioperative patient’s clinical pathways designed to achieve early recovery after …
[HTML][HTML] Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
… Alexandre de Nonneville declares the following competing interest: Daiichi Sankyo (lecture
fees, congress invitation), Gilead (lecture fees, congress invitation), MSD (congress invitation…
fees, congress invitation), Gilead (lecture fees, congress invitation), MSD (congress invitation…
[HTML][HTML] Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
F Bertucci, V Niziers, A de Nonneville… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Soft-tissue sarcomas (STSs) are heterogeneous and aggressive tumors, with
high metastatic risk. The immunologic constant of rejection (ICR) 20-gene signature is a …
high metastatic risk. The immunologic constant of rejection (ICR) 20-gene signature is a …
Adjuvant chemotherapy for small, lymph node–negative, triple‐negative breast cancer: A single‐center study and a meta‐analysis of the published literature
…, R Luo, H Li, F Xu, Z Yuan, S Wang, A de Nonneville… - Cancer, 2020 - Wiley Online Library
Background Current guidelines recommend adjuvant chemotherapy for patients with small,
lymph node–negative, triple‐negative breast cancer (TNBC) measuring >5 mm (T1b disease)…
lymph node–negative, triple‐negative breast cancer (TNBC) measuring >5 mm (T1b disease)…
[HTML][HTML] The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
A Giraudo, R Sabatier, F Rousseau, A De Nonneville… - Cancers, 2024 - mdpi.com
Simple Summary This position paper aims to address specific clinical questions regarding
the use of cyclin-dependent kinase 4/6 inhibitors in elderly patients with early or advanced …
the use of cyclin-dependent kinase 4/6 inhibitors in elderly patients with early or advanced …